AACR-2016 Clinical Trial Post #1: IMMU-130
Clinical trial abstracts of the AACR meeting next week were released this afternoon. AACR presents some clinical trial results - the ASCO conference in June presents much more. A lot of eyes will be on the PD1/Avastin/FOLFOX trial results which will be presented on Monday to see if they mention MSS-CRC. Once I hear feedback what was said, I'll post next week on that one.
Today I'll post (3) clinical trial poster abstracts I noticed with CRC data and with currently open trials.
Title; Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results
Open Trial: https://clinicaltrials.gov/ct2/show/NCT ... 130&rank=1
Mechanism: Antibody-linked Irinotecan for a tumor targeted approach. Tested against patients who had failed irinotecan.
CRC Data: Eleven pts (78%) at 10 mg/kg QW in 21-day cycles (N=19) had stable disease compared to 7 pts (44%) at 6 mg/kg BIW (N=19). One pt had a confirmed PR (88% shrinkage) at 6 mg/kg BIW dose, and then maintained PR at 8 mg/kg QW for 3-wk cycles over 2 yrs. Median PFS at 10 mg/kg QW was 4.6 mos.
Side effects: Quote from abstract "Appearing less than Irinotecan"
Full abstract: http://www.abstractsonline.com/plan/Vie ... 0fb1922267